[Anti-Helicobacter pylori treatment in patients with idiopathic thrombocytopenic purpura].

Department of Clinic Laboratory Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 12/2009; 34(12):1251-4.
Source: PubMed

ABSTRACT To observe the effect of anti-Helicobacter pylori (H.pylori) treatment on patients with idiopathic thrombocytopenic purpura (ITP) and its effect on blood platelet.
From April 2006 to April 2008, a total of 31 patients diagnosed as having ITP and H. pylori infection were collected. These patients were given standard antibiotic therapy for H. pylori eradication (omeprazole 20 mg, clarithromycin 0.5 g, and amoxicillin 1.0 g, twice per day for 1 week). The effect of anti-H. pylori treatment was analyzed, and the blood platelets were counted before the treatment and on day 7, 14, and 28 after the treatment.
Of the 31 ITP patients with H. pylori infection, 21 were cured and 10 were not effective, with the effective rate 67.74%. Blood platelet increased in the cured group but did not change in the no-effect group.
Anti-H. pylori treatment could increase the blood platelet, and H. pylori infection may be related to the reduction of blood platelet in ITP patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Helicobacter pylori (H. pylori) is the most common infection in humans, with a marked disparity between developed and developing countries. Although H. pylori infections are asymptomatic in most infected individuals, they are intimately related to malignant gastric conditions such as gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma and to benign diseases such as gastritis and duodenal and gastric peptic ulcers. Since it was learned that bacteria could colonize the gastric mucosa, there have been reports in the medical literature of over 50 extragastric manifestations involving a variety medical areas of specialization. These areas include cardiology, dermatology, endocrinology, gynecology and obstetrics, hematology, pneumology, odontology, ophthalmology, otorhinolaryngology and pediatrics, and they encompass conditions with a range of clear evidence between the H. pylori infection and development of the disease. This literature review covers extragastric manifestations of H. pylori infection in the hematology field. It focuses on conditions that are included in international consensus and management guides for H. pylori infection, specifically iron deficiency, vitamin B12 (cobalamin) deficiency, immune thrombocytopenia, and MALT lymphoma. In addition, there is discussion of other conditions that are not included in international consensus and management guides on H. pylori, including auto-immune neutropenia, antiphospholipid syndrome, plasma cell dyscrasias, and other hematologic diseases.
    World Journal of Gastroenterology 09/2014; 20(36):12818-12838. DOI:10.3748/wjg.v20.i36.12818 · 2.43 Impact Factor